Physician

Marnie J Marker, M.D.

According to 2025 Medicare claims, Marnie Marker, M.D. (NPI: 1013978220) practices nephrology in the Wheeling, WV-OH market, with the plurality of this provider's patient population coming from Belmont, OH. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES, INC (NPI: 1457430134; TIN: 550667825) and primary practice location at 26003-6379. Marker is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Marker's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 358 traditional Medicare patients, billed 982 HCPCS/CPT codes, and received $118,461 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 996 prescription claims across 200 beneficiaries totaling $274,613 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 56 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $238,082 and ending at $274,613. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	482	1,359	$118,480
2016	492	1,425	$125,115
2017	527	1,557	$152,712
2018	500	1,736	$147,969
2019	518	2,011	$172,554
2020	503	1,795	$161,406
2021	431	1,289	$142,075
2022	372	1,199	$110,760
2023	388	1,113	$114,080
2024	358	982	$118,461

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	244	1,795	$238,082
2016	257	1,738	$242,302
2017	263	1,926	$318,844
2018	283	1,946	$149,287
2019	231	1,465	$99,484
2020	207	1,206	$113,913
2021	210	1,096	$118,932
2022	204	1,088	$154,537
2023	203	997	$173,252
2024	200	996	$274,613

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	63	$6,711
2016	N/R	56	$8,543
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$724
2021	N/R	26	$486
2022	N/R	58	$864
2023	N/R	56	$2,674
2024	N/R	56	$2,278

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	54	120	$280
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	63	70	$140
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	80	265	$96
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	155	196	$95
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	46	122	$63

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	115	5,758	$105,661
Jardiance	Empagliflozin	76	3,455	$66,170
Kerendia	Finerenone	44	1,780	$37,014
Lokelma	Sodium Zirconium Cyclosilicate	44	1,234	$21,973
Veltassa	Patiromer Calcium Sorbitex	15	600	$13,780

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	13	$1,034
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	13	$805
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$213

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Marnie J. Marker, M.D.?

Tedicare shows public-source Medicare data for Marnie J. Marker, M.D. (NPI 1013978220), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marnie J. Marker, M.D. have ACO affiliation data?

Marnie J. Marker, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Marnie J. Marker, M.D.?

Marnie J. Marker, M.D. is linked to NEPHROLOGY ASSOCIATES, INC (billing NPI 1457430134) in the available physician profile data.

Does Marnie J. Marker, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.